NCT02170376View on ClinicalTrials.gov

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Parkinson's Disease (PD)
Interventions
DRUG

BIA 9-1067

BIA 9-1067 25 mg and 50 mg

DRUG

Entacapone

Entacapone (ENT), over-encapsulated tablet 200 mg

DRUG

Placebo

PLC, placebo

DRUG

Levodopa/carbidopa

Levodopa/carbidopa, tablet 100/25 mg

Trial Locations (1)

75015

SGS aster, Paris

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02170376 - The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | Biotech Hunter | Biotech Hunter